• LAST PRICE
    48.0700
  • TODAY'S CHANGE (%)
    Trending Up2.5400 (5.5787%)
  • Bid / Lots
    44.0000/ 5
  • Ask / Lots
    48.3000/ 1
  • Open / Previous Close
    45.8600 / 45.5300
  • Day Range
    Low 45.0100
    High 48.3900
  • 52 Week Range
    Low 29.5000
    High 78.0000
  • Volume
    261,205
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 45.53
TimeVolumeVERV
09:32 ET6748846.005
09:34 ET138046.43
09:36 ET40046.65
09:41 ET52846.935
09:43 ET70046.59
09:45 ET10046.66
09:50 ET51247.17
09:56 ET20047.34
09:57 ET30047.4799
09:59 ET22747.7
10:01 ET20047.78
10:03 ET50047.69
10:06 ET40047.82
10:08 ET95948.29
10:10 ET10048.3
10:12 ET123247.655
10:14 ET59647.45
10:15 ET10047.395
10:17 ET20047.37
10:19 ET10047.44
10:21 ET10047.56
10:24 ET10047.745
10:28 ET463247.1
10:30 ET355747.2698
10:32 ET613946.73
10:33 ET370046.9
10:35 ET145247.02
10:37 ET240046.75
10:39 ET152546.47
10:42 ET770046.29
10:44 ET304546.04
10:46 ET354546.32
10:48 ET185046.34
10:50 ET10046.33
10:51 ET30046.395
10:53 ET20046.32
10:55 ET50046.22
10:57 ET10046.27
11:00 ET530046.18
11:02 ET20046.22
11:04 ET10046.245
11:08 ET50046.02
11:09 ET20046.05
11:11 ET10046.07
11:13 ET40045.85
11:18 ET80045.95
11:20 ET60046.08
11:27 ET710046.5
11:31 ET30046.83
11:33 ET20046.62
11:36 ET60046.99
11:45 ET40047.11
11:49 ET120047.21
11:51 ET61447.18
11:54 ET20047.24
11:56 ET10047.4206
12:02 ET10047.15
12:05 ET10047.325
12:07 ET10047.44
12:09 ET80547.6
12:12 ET30047.51
12:16 ET20047.47
12:18 ET30047.25
12:20 ET160047.56
12:21 ET204347.58
12:23 ET40047.405
12:27 ET83847.08
12:30 ET60046.99
12:34 ET10046.94
12:43 ET10046.89
12:54 ET70047.115
12:56 ET60047.525
12:57 ET20047.46
01:03 ET60047.49
01:08 ET20047.555
01:10 ET20047.42
01:12 ET10047.35
01:14 ET20047.09
01:15 ET10047.26
01:17 ET10047.445
01:24 ET20047.33
01:28 ET80047.41
01:33 ET30047.57
01:35 ET100047.55
01:37 ET20047.34
01:39 ET30047.43
01:42 ET80047.55
01:44 ET30047.37
01:46 ET10047.5028
01:50 ET10047.415
01:55 ET230047
01:57 ET50047.01
02:00 ET80047.2
02:06 ET10047.05
02:08 ET110047.3
02:11 ET40047.205
02:20 ET10047.18
02:22 ET40047.44
02:24 ET20047.505
02:26 ET61047.41
02:27 ET10047.52
02:29 ET50047.4
02:31 ET40047.22
02:33 ET50047.475
02:38 ET10047.39
02:40 ET80047.25
02:45 ET22147.24
02:54 ET120047.495
02:56 ET10047.57
03:02 ET180047.44
03:03 ET10047.52
03:12 ET62047.45
03:14 ET300047.48
03:16 ET70047.61
03:18 ET120047.4
03:20 ET30047.41
03:21 ET30047.39
03:23 ET50047.43
03:25 ET30047.61
03:27 ET10047.57
03:30 ET100047.46
03:32 ET50047.53
03:34 ET40047.36
03:36 ET140047.505
03:38 ET57947.49
03:39 ET140147.405
03:41 ET160047.41
03:43 ET40047.39
03:45 ET50047.49
03:48 ET70047.43
03:50 ET260447.575
03:52 ET224947.64
03:54 ET132447.84
03:56 ET371147.8875
03:57 ET269248.02
03:59 ET1784648.07
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVERV
Verve Therapeutics Inc
2.2B
0.0x
---
United StatesATAI
ATAI Life Sciences NV
2.2B
0.0x
---
United StatesADCT
ADC Therapeutics SA
2.1B
-11.0x
---
United StatesALXO
ALX Oncology Holdings Inc
2.2B
-28.0x
---
United StatesERAS
Erasca Inc
2.2B
0.0x
---
United StatesALLO
Allogene Therapeutics Inc
2.3B
-9.4x
---
As of 2021-10-28

Company Information

Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.

Contact Information

Headquarters
500 Technology SquareCAMBRIDGE, MA, United States 02139
Phone
978-501-3026
Fax
302-655-5049

Executives

Chairman of the Board, Co-Founder
Burt Adelman
President, Chief Operating Officer
Andrew Ashe
Chief Executive Officer, Co-Founder, Director
Sekar Kathiresan
Chief Scientific Officer
Andrew Bellinger
Senior Director - Finance
Maggie Beaudoin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.2B
Revenue (TTM)
---
Shares Outstanding
48.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
$1.33
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.